Aktienanalyse zu Ligand Pharmaceuticals Inc (LGND)LGNDLigand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ligand Pharmaceuticals appears to be a good buy right now due to its current price of $301.81, which is significantly lower than the average analyst price target of $358, indicating a potential upside of approximately 18.5%. Additionally, the company has shown a strong gross margin of 82.24% in Q2 2026, which reflects its operational efficiency and profitability. However, a risk to consider is the recent net income loss of $13.35 million in Q1 2026, which highlights ongoing financial challenges that could affect future performance.

6 analysts cover LGND: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 237.20.